MSH2 and melanoma: For instance, an unprecedented overall survival rate exceeding 7 years was reported for a patient with metastatic melanoma lacking the expression of MMR gene MSH6 [202], while in a preclinical melanoma model, knockdown of MSH2 in poorly immunogenic tumors markedly improved the response to anti-PD-1 immunotherapy [203].